Cefazolin

The dosage of Cefazolin for adults depends entirely on the type and severity of the infection being treated. Healthcare providers typically use the following guidelines:

• Mild Infections (Gram-positive cocci): 250 mg to 500 mg every 8 hours.
• Moderate to Severe Infections: 500 mg to 1 gram every 6 to 8 hours.
• Severe, Life-Threatening Infections (e.g., endocarditis, septicemia): 1 gram to 1.5 grams every 6 hours. In rare cases, doses up to 12 grams per day have been used.
• Acute Uncomplicated Urinary Tract Infections: 1 gram every 12 hours.
• Surgical Prophylaxis: To prevent infection during surgery, a dose of 1 to 2 grams is typically administered IV or IM approximately 30 to 60 minutes before the start of the procedure. For long surgeries (over 3 hours), an additional dose of 500 mg to 1 gram may be given during the operation. Post-operative doses of 500 mg to 1 gram every 6 to 8 hours may be continued for 24 hours after surgery.

Cefazolin is approved for use in pediatric patients, including neonates. Dosing is strictly calculated based on the child's weight (mg/kg).

• General Infections (Children > 1 month): The standard dose is 25 to 50 mg per kg of body weight per day, divided into 3 or 4 equal doses. For severe infections, this may be increased to 100 mg/kg/day.
• Neonates (under 1 month): Because neonatal renal function is immature, dosing intervals are usually longer (e.g., every 12 hours). A common dose is 20 mg/kg every 8 to 12 hours.
• Pediatric Surgical Prophylaxis: A single dose of 30 mg/kg (up to a maximum of 2 grams) is usually given before surgery.

Renal Impairment

Since Cefazolin is primarily cleared by the kidneys, patients with decreased renal function require lower doses or longer intervals between doses to prevent toxic accumulation.

• Creatinine Clearance (CrCl) 35-54 mL/min: Full dose, but extend interval to at least every 8 hours.
• CrCl 11-34 mL/min: Give 50% of the usual dose every 12 hours.
• CrCl <10 mL/min: Give 50% of the usual dose every 18 to 24 hours.
• Hemodialysis: Patients on dialysis typically receive a supplemental dose after each dialysis session because the drug is filtered out of the blood.

Hepatic Impairment

No specific dosage adjustments are usually required for patients with liver disease, as Cefazolin is not significantly metabolized by the liver. However, clinical monitoring remains important.

Elderly Patients

Older adults often have age-related declines in kidney function. Healthcare providers should calculate the creatinine clearance for elderly patients and adjust the Cefazolin dose accordingly to avoid side effects like neurotoxicity.

Cefazolin is administered by a healthcare professional in a clinical setting (hospital, clinic, or infusion center). If you are receiving Cefazolin at home through a home-infusion service:

• Storage: Follow specific storage instructions. Some pre-mixed bags must be kept in the refrigerator and brought to room temperature before use. Never freeze pre-mixed bags unless instructed.
• Administration: Ensure the IV site is clean. Administer the drug over the exact timeframe prescribed (usually 30 minutes).
• Visual Inspection: Always check the solution for particles or discoloration before use. If the liquid is cloudy or contains floating specks, do not use it.

If you are receiving this medication in a hospital, your nurses will manage the schedule. If you miss an appointment for an infusion or miss a dose at home, contact your doctor or infusion nurse immediately. Do not 'double up' the next dose to catch up, as this increases the risk of side effects.

An overdose of Cefazolin can lead to serious neurological complications, especially in patients with kidney disease. Symptoms of overdose include:

• Seizures (convulsions)
• Extreme dizziness
• Paresthesia (tingling or 'pins and needles' sensation)
• Cardiac arrhythmias (irregular heartbeat)

In the event of a suspected overdose, emergency medical treatment is required. Hemodialysis may be used to help remove the drug from the bloodstream quickly.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the treatment early without medical guidance, as this can lead to the return of the infection and antibiotic resistance.

While Cefazolin is generally well-tolerated, some patients may experience mild side effects. These often resolve as the body adjusts to the medication or once the treatment course is completed.

• Gastrointestinal Upset: Diarrhea is the most common side effect. Some patients also experience nausea or occasional vomiting. This occurs because the antibiotic can disrupt the natural balance of 'good' bacteria in the gut.
• Injection Site Reactions: Pain, swelling, or redness at the site of the IV or IM injection is common. In some cases, inflammation of the vein (phlebitis) can occur during IV infusion.
• Oral Thrush or Vaginal Yeast Infection: By altering the body's natural flora, Cefazolin can allow an overgrowth of Candida (yeast), leading to white patches in the mouth or vaginal itching and discharge.

• Skin Rash: A mild, itchy red rash or hives (urticaria) may develop. This is often a sign of a mild allergic sensitivity.
• Loss of Appetite (Anorexia): Some patients report a decreased interest in food or a metallic taste in the mouth during treatment.
• Elevated Liver Enzymes: Transient increases in AST, ALT, or alkaline phosphatase may be seen on blood tests, usually without symptoms of liver damage.

• Hematologic Changes: Rare cases of decreased white blood cell counts (leukopenia or neutropenia) or decreased platelets (thrombocytopenia) have been reported. This can increase the risk of infection or bruising.
• Drug Fever: A fever that occurs as a direct reaction to the medication itself, rather than the underlying infection.
• Eosinophilia: An increase in a specific type of white blood cell often associated with allergic reactions.

> Warning: Stop receiving Cefazolin and call your doctor immediately or seek emergency care if you experience any of the following:

1. 1Anaphylaxis (Severe Allergic Reaction): Symptoms include swelling of the face, lips, or throat; difficulty breathing or wheezing; a rapid pulse; and a sharp drop in blood pressure (fainting).
2. 2Clostridioides difficile-Associated Diarrhea (CDAD): This is a severe form of diarrhea caused by a toxin-producing bacterium. Symptoms include watery or bloody stools, severe stomach cramps, and fever. This can occur even weeks after the antibiotic treatment has ended.
3. 3Severe Skin Reactions: Rare but life-threatening conditions like Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). Watch for skin peeling, blistering, or a painful purple/red rash that spreads.
4. 4Neurotoxicity/Seizures: Especially in patients with kidney impairment, high levels of Cefazolin can trigger seizures, confusion, or involuntary muscle twitching (myoclonus).
5. 5Nephrotoxicity: Signs of kidney damage, such as a significant decrease in urine output, swelling in the legs or ankles, or blood in the urine.
6. 6Hepatotoxicity

Cefazolin is typically used for short-term acute treatment. However, prolonged use (weeks) can lead to:

• Superinfection: The emergence of resistant bacteria or fungi that are not killed by Cefazolin, requiring different treatments.
• Vitamin K Deficiency: In rare cases, long-term use of cephalosporins can interfere with Vitamin K production in the gut, potentially leading to bleeding problems, especially in malnourished patients or those with liver disease.
• Positive Coombs Test: Long-term use can cause a positive result on a Coombs test (a blood test for antibodies), which might complicate blood typing or indicate a rare form of anemia (hemolytic anemia).

No FDA black box warnings currently exist for Cefazolin. However, the FDA requires warnings regarding the risk of hypersensitivity reactions and C. difficile-associated diarrhea on all cephalosporin labels.

Report any unusual symptoms to your healthcare provider promptly. Early detection of side effects often allows for safer management or a transition to an alternative therapy.

Cefazolin is a potent antibiotic that must be used with caution. Before starting treatment, patients must inform their healthcare provider of their full medical history, particularly any history of allergies to medications. The most significant risk associated with Cefazolin is a severe allergic reaction. While it is a first-generation cephalosporin, it shares structural similarities with penicillins. Patients with a history of immediate, severe allergic reactions to penicillin (such as anaphylaxis or hives) should generally avoid Cefazolin due to the risk of cross-reactivity.

There are no FDA black box warnings for Cefazolin. However, it carries significant 'Warnings and Precautions' that are critical for patient safety.

• Allergic Reactions / Anaphylaxis Risk: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported. If an allergic reaction occurs, the drug must be discontinued immediately. It is vital to distinguish between a mild rash and the onset of anaphylaxis.
• Clostridioides difficile-Associated Diarrhea (CDAD): Nearly all antibacterial agents, including Cefazolin, can cause CDAD. This ranges in severity from mild diarrhea to fatal colitis (inflammation of the colon). Treatment with Cefazolin alters the normal flora of the colon, leading to overgrowth of C. difficile.
• Seizure Potential: Like other beta-lactams, Cefazolin can cause neurological adverse effects, including seizures. This risk is highest in patients with renal impairment who receive doses that are not appropriately reduced.
• Prothrombin Time Prolongation: Some cephalosporins have been associated with a fall in prothrombin activity (increased bleeding risk). Patients at risk include those with renal or hepatic impairment, poor nutritional status, or those on prolonged antibiotic therapy.
• Development of Drug-Resistant Bacteria: Prescribing Cefazolin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit and increases the risk of the development of drug-resistant bacteria.

Patients receiving prolonged courses of Cefazolin (e.g., for osteomyelitis or endocarditis) require regular monitoring to ensure safety:

• Complete Blood Count (CBC): To check for leukopenia or thrombocytopenia.
• Renal Function Tests: Monitoring serum creatinine and BUN (Blood Urea Nitrogen) is essential, especially in the elderly or those with known kidney disease.
• Liver Function Tests (LFTs): To monitor for transient elevations in liver enzymes.
• Prothrombin Time (PT/INR): In patients at risk for bleeding or those taking anticoagulants like Warfarin.

Cefazolin generally does not interfere with the ability to drive or operate machinery. However, if you experience side effects such as dizziness, confusion, or seizures, you should avoid these activities and contact your doctor immediately.

While Cefazolin does not have a classic 'disulfiram-like' reaction with alcohol (unlike some other cephalosporins like Cefotetan), it is generally advised to avoid alcohol while fighting a serious infection. Alcohol can dehydrate the body and interfere with the immune system's ability to recover.

It is critical to complete the full course of Cefazolin as prescribed by your doctor. Stopping the medication early, even if you feel better, can allow the remaining bacteria to multiply and develop resistance, making the infection much harder to treat in the future.

> Important: Discuss all your medical conditions, especially kidney disease and past drug allergies, with your healthcare provider before starting Cefazolin.

There are few absolute contraindications for drug combinations with Cefazolin; however, it should never be used in patients with a known severe allergy to other cephalosporins. Additionally, the use of live attenuated vaccines (such as the oral typhoid vaccine or BCG vaccine) should be avoided during Cefazolin therapy. Antibiotics can kill the live bacteria in the vaccine, rendering the immunization ineffective. It is recommended to wait at least 48 to 72 hours after the last dose of Cefazolin before receiving a live bacterial vaccine.

• Aminoglycosides (e.g., Gentamicin, Tobramycin): Using Cefazolin concurrently with aminoglycosides may increase the risk of nephrotoxicity (kidney damage). If these drugs must be used together, kidney function must be monitored very closely.
• Warfarin (Coumadin): Cephalosporins can enhance the anticoagulant effect of Warfarin by interfering with Vitamin K synthesis in the gut. This increases the risk of bleeding. Healthcare providers will monitor the INR (International Normalized Ratio) more frequently and may need to adjust the Warfarin dose.

• Probenecid: Probenecid is a medication used for gout that blocks the renal tubular secretion of Cefazolin. Taking these together will result in higher and more prolonged blood levels of Cefazolin. While sometimes used intentionally to boost antibiotic levels, it can also increase the risk of side effects.
• Loop Diuretics (e.g., Furosemide/Lasix): Some studies suggest that high doses of cephalosporins combined with potent diuretics may increase the risk of kidney impairment.

Since Cefazolin is administered by injection, food does not affect its absorption. There are no known interactions with grapefruit, dairy, or high-fat meals. However, maintaining adequate hydration is important while being treated for an infection to support kidney function and drug clearance.

• Vitamin K: Since Cefazolin can lower Vitamin K levels, taking large amounts of Vitamin K supplements might theoretically counteract some effects, though this is rarely a clinical concern unless the patient has a bleeding disorder.
• Probiotics: While many patients take probiotics to prevent antibiotic-associated diarrhea, they should be taken a few hours apart from the Cefazolin dose (if possible) to ensure the antibiotic doesn't simply kill the probiotic bacteria.
• St. John's Wort: There is no known direct interaction, but St. John's Wort can affect many other medications; always inform your doctor.

Cefazolin can interfere with certain laboratory tests, leading to false results:

• Urinary Glucose Tests: It may cause a false-positive reaction for glucose in the urine when using copper reduction tests (like Benedict's solution or Clinitest). It does not affect glucose oxidase-based tests (like Diastix).
• Coombs Test: A false-positive direct Coombs test may occur. This is important for blood banks to know if a patient requires a blood transfusion.
• Creatinine Tests: High concentrations of Cefazolin can interfere with the Jaffe reaction, leading to falsely elevated serum creatinine readings.

For each major interaction, the mechanism usually involves either competitive inhibition of renal excretion (Probenecid) or additive toxic effects on the kidneys (Aminoglycosides). Management strategies involve dose adjustment, increased monitoring, or choosing alternative therapies.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter drugs.

Cefazolin is strictly contraindicated in certain individuals to prevent life-threatening complications. These include:

1. 1Known Cephalosporin Allergy: Any patient who has had a documented severe allergic reaction (anaphylaxis, angioedema, Stevens-Johnson Syndrome) to Cefazolin or any other cephalosporin antibiotic (e.g., Cephalexin, Ceftriaxone, Cefdinir) must not receive this drug. The mechanism is an IgE-mediated hypersensitivity reaction to the beta-lactam ring or side chains.
2. 2Severe Penicillin Allergy: While not an absolute contraindication for all, patients with a history of immediate-type hypersensitivity (anaphylaxis) to penicillins are generally excluded from receiving Cefazolin. There is a 1% to 10% risk of cross-sensitivity between these drug classes due to their shared beta-lactam structure.

These are conditions where the drug should be used only if the benefits clearly outweigh the risks, and with extreme caution:

• Renal Insufficiency: Patients with significantly impaired kidney function are at high risk for Cefazolin-induced neurotoxicity (seizures). While not a reason to avoid the drug entirely, it requires strict dose modification.
• History of Gastrointestinal Disease: Particularly colitis. Patients with a history of C. difficile or ulcerative colitis may be at higher risk for severe antibiotic-associated colitis.
• Seizure Disorders: Because Cefazolin can lower the seizure threshold, patients with known epilepsy should be monitored closely.
• Poor Nutritional Status: Patients who are malnourished or have Vitamin K deficiencies are at a higher risk for bleeding complications when taking Cefazolin.

As mentioned, cross-sensitivity is a major concern. If you are allergic to one beta-lactam (like Amoxicillin or Penicillin VK), there is a chance your immune system will recognize Cefazolin as a threat. Always provide a detailed description of your past allergic reactions (e.g., 'I got a small rash' vs. 'I couldn't breathe') to your healthcare provider so they can make an informed decision.

> Important: Your healthcare provider will evaluate your complete medical history and the severity of your infection before prescribing Cefazolin. Always wear a medical alert bracelet if you have a severe drug allergy.

Cefazolin is classified as FDA Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.

• Trimester-Specific Risks: Cefazolin readily crosses the placenta and can be detected in the amniotic fluid. However, it is generally considered one of the safer antibiotics to use during pregnancy when a bacterial infection is present. It is often used for surgical prophylaxis during Cesarean sections.
• Clinical Use: It should be used during pregnancy only if clearly needed. Healthcare providers typically weigh the risk of an untreated infection (which can harm both mother and baby) against the minimal theoretical risk of the medication.

Cefazolin is excreted in human milk in very low concentrations. According to the American Academy of Pediatrics, it is generally considered compatible with breastfeeding.

• Risks to Infant: The main concerns for a nursing infant are the potential for a change in bowel habits (diarrhea), the development of oral thrush, or the rare possibility of becoming sensitized to the drug (developing an allergy).
• Risk-Benefit: Most experts agree that the benefits of breastfeeding outweigh the minimal risks of Cefazolin exposure through milk.

Cefazolin is safe and effective for use in children, including infants over one month of age.

• Safety: The safety profile in children is similar to that in adults.
• Premature Infants: Safety in premature infants and neonates under one month of age has not been as extensively documented, though it is frequently used in neonatal intensive care units (NICUs) with adjusted dosing intervals due to immature kidney function.
• Growth Effects: There are no known adverse effects of Cefazolin on bone growth or development in children.

Clinical studies of Cefazolin did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. However:

• Renal Clearance: The most significant concern in the elderly is the natural decline in kidney function. Since Cefazolin is renally excreted, the risk of toxic reactions is higher in patients with impaired renal function.
• Polypharmacy: Elderly patients are more likely to be on other medications (like diuretics or blood thinners) that can interact with Cefazolin.
• Dosing: Doctors usually start at the lower end of the dosing range and monitor kidney function closely.

In patients with a Creatinine Clearance (CrCl) of less than 55 mL/min, the half-life of Cefazolin increases significantly. Dose adjustments are mandatory (see Usage Instructions). For patients on hemodialysis, Cefazolin is dialyzable; roughly 20-50% of the drug is removed during a standard session, requiring a 'top-up' dose afterward.

No dosage adjustment is generally required for patients with liver disease (Child-Pugh Class A, B, or C). However, because these patients may also have underlying coagulopathies (bleeding issues), they should be monitored for any signs of increased bruising or bleeding.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.

Cefazolin is a bactericidal beta-lactam antibiotic. Its primary molecular target is the Penicillin-Binding Proteins (PBPs) located on the inner membrane of the bacterial cell wall. These PBPs (specifically PBP-1, PBP-2, and PBP-3) are enzymes responsible for the assembly and maintenance of the peptidoglycan layer. Cefazolin acts as a structural analog of the D-alanyl-D-alanine portion of the peptidoglycan precursor. By binding covalently to the active site of the PBPs, Cefazolin inhibits the transpeptidation reaction. This prevents the formation of cross-links between peptidoglycan chains, leading to a loss of structural integrity. The resulting osmotic instability causes the bacterial cell to swell and burst (lysis).

• Time-Dependent Killing: Like other beta-lactams, Cefazolin exhibits time-dependent killing. This means its efficacy is best predicted by the amount of time the concentration of the drug remains above the Minimum Inhibitory Concentration (MIC) of the target bacteria (T > MIC).
• Spectrum of Activity: It is highly active against Gram-positive aerobes, including Staphylococcus aureus (methicillin-susceptible), Staphylococcus epidermidis, and various species of Streptococcus. It also has moderate activity against some Gram-negative aerobes like Escherichia coli, Proteus mirabilis, and Klebsiella species. It is NOT active against MRSA, Enterococcus, or Pseudomonas.
• Resistance: Bacteria develop resistance to Cefazolin primarily through the production of beta-lactamase enzymes, which cleave the antibiotic's ring structure, or by altering their PBPs so the drug can no longer bind.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Administered IV/IM) |

| Protein Binding | 70% to 85% |

| Half-life | 1.8 to 2.0 hours (Normal Renal Function) |

| Tmax | 1-2 hours (IM); Immediate (IV) |

| Metabolism | Minimal (Hepatic) |

| Excretion | Renal (80-100% unchanged) |

• Molecular Formula: C14H14N8O4S3 (Cefazolin)
• Molecular Weight: 454.5 g/mol
• Solubility: Freely soluble in water; very slightly soluble in alcohol.
• Structure: It contains a beta-lactam ring fused to a six-membered dihydrothiazine ring (the cephem nucleus), with a thiadiazole side chain at the 3-position and a tetrazolylacetamido group at the 7-position.

Cefazolin is a First-Generation Cephalosporin. Related medications in this class include Cephalexin (Keflex) and Cefadroxil (Duricef). While later generations (2nd, 3rd, 4th) offer broader Gram-negative coverage, first-generation agents like Cefazolin remain superior for most susceptible Gram-positive skin and soft tissue infections.